LOGIN

PASSWORD SUCCESFULLY RESET

LOGIN

Skip to content

Targeted Cancer Therapies

of Claire Elizabeth Powers Smith, Vinayak Prasad • April 2021
Targeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy. For example, the monoclonal antibodies trastuzumab and pertuzumab target human epidermal growth factor receptor 2 (HER2) and are used when treating HER2-positive breast cancer. Although targeted oncology has improved survival by years for some incurable cancers such as metastatic breast and lung cancer, as few as 8% of patients with advanced cancer qualify for targeted oncology medications, and even fewer benefit. Other limitations include serious adverse events, illustrated by a 20% to 30% rate of heart attack, stroke, or peripheral vascular events among patients taking ponatinib, which is used in treating chronic myelogenous leukemia. Immune checkpoint inhibitor therapy–related adverse effects such as hypothyroidism are common, and more severe adverse events such as colitis and pneumonitis can be fatal and require immediate intervention. Drug interactions with widely prescribed medications such as antacids and warfarin are common. Additionally, financial toxicities are a problem for patients with cancer who are using costly targeted therapies. Future directions for targeted oncology include tumor-agnostic drugs, which target a given mutation and could be used in treating cancers from multiple organ types. An overview of indications, mechanism of action, and toxicities of targeted cancer therapies is offered here.

(Am Fam Physician. 2021;103(3):155-163. Copyright © 2021 American Academy of Family Physicians.)

Related Articles

I disturbi d'ansia nei bambini e negli adolescenti

I disturbi d'ansia nei bambini e negli adolescenti

of
Dr.ssa Alicia Kowalchuk, dr.ssa Sandra J. Gonzalez, dr. Roger J. Zoorob
September 2024

Highlights

Iscriviti per accedere ai contenuti digitali

LOGIN

Puoi accedere al sito di Minuti Digitale con le stesse credenziali dell’area riservata del sito di Fondazione Internazionale Menarini

non sei ancora registrato? premi QUI per iniziare

hai dimenticato la tua password? resetta la password

Ricerca Edizione

Search Edition:

SIGN UP FOR FREE ACCESS TO THE DIGITAL CONTENT

LOGIN

You can access the Minuti Digitale website with the same credentials as those used for registering on the Fondazione Internazionale Menarini website

not registered? click here

forgot your password? reset your password

INSCRÍBASE PARA ACCEDER A LOS CONTENIDOS DIGITALES

LOGIN

Puede acceder al sitio de Minuti Digitale con las mismas credenciales del área reservada del sitio de la Fondazione Internazionale Menarini

no estas registrado? premi QUI

Olvidaste tu contraseña? restablecer la contraseña

Reset Password

Inserisci il tuo indirizzo email per ottenere un link di reset password.

 

Effettuerai il reset sul sito di Fondazione Menarini e potrai successivamente effettuare il login su Minuti con le stesse credenziali.

Reset Password

Enter your email address to obtain a password resetting link.

 

After performing the resetting on the Fondazione Menarini website, you can then log in to Minuti with the same credentials.

Reset Password

Introduzca su dirección de correo electrónico para obtener el enlace para restablecer su contraseña.

 

Llevará a cabo el restablecimiento en el sitio de la Fondazione Menarini y luego podrá iniciar sesión en Minuti con las mismas credenciales.

error: Download disabled!